28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
The disturbances of the cholesterol synthesis and metabolism described in Alzheimer's disease (AD) may be both a consequence of the neurodegenerative process and a contributor to the pathogenesis. 2 key findings →
Participants: 86 Evidence: low
Full summary, score breakdown and related studies → Original source
DNA methyltransferase 1 (DNMT1) is crucial for maintenance of methylation, gene regulation and chromatin stability. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The Galveston Orientation and Amnesia Test (GOAT) was developed to evaluate cognition serially during the subacute stage of recovery from closed head injury. 1 key finding →
Participants: 50 Evidence: low
Full summary, score breakdown and related studies → Original source
Significant weight reduction ability of semaglutide has been demonstrated in various phase-3 clinical trials, for which recently semaglutide became the first long-acting GLP-1 receptor agonist to be approved by the United States Food and Drug Administration for management of obesity. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent clinical guidelines have emphasized the importance of screening for cognitive impairment in older adults with diabetes, however, there is still a lack of understanding about the drug therapy. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Human Islet amyloid polypeptide (hIAPP) from pancreatic β cells in the islet of Langerhans has different physiological functions including inhibiting the release of insulin and glucagon. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Obesity in women of reproductive age has a number of adverse metabolic effects, including Type II Diabetes (T2D), dyslipidemia, and cardiovascular disease. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Traumatic brain injury (TBI), either as an isolated injury or in conjunction with other injuries, is an increasingly common event. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
A number of well-designed epidemiological studies have linked type 2 diabetes mellitus (T2DM) with an increased risk of Alzheimer's disease (AD). 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source
Statins are a family of drugs that are used for treating hyperlipidaemia with a recognized capacity to prevent cardiovascular disease events. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Metformin has been designated as one of the most crucial first-line therapeutic agents in the management of type 2 diabetes mellitus. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Clinical and pathological data from the Rush Memory and Aging Project were used to test the hypothesis that distress proneness is associated with increased risk of Alzheimer's disease (AD). 3 key findings →
Participants: 55 Evidence: low
Full summary, score breakdown and related studies → Original source
In older men, pathways occurred from chronic stress to distress to the metabolic syndrome, which in turn predicted CHD. 1 key finding →
Participants: 47 Evidence: low
Full summary, score breakdown and related studies → Original source
Although a causal association remains to be determined, epidemiologic evidence suggests an association between hearing loss and increased risk of dementia. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Inflammation is a natural protective mechanism that occurs when the body's tissue homeostatic mechanisms are disrupted by biotic, physical, or chemical agents. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The increasing amount of particulate matter (PM) in the ambient air is a pressing public health issue globally. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The aging population worldwide is facing a significant increase in age-related non-communicable diseases, including cardiovascular and brain pathologies. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These data demonstrate that chronic exposure to ambient TRAP promoted AD phenotypes in wildtype and genetically susceptible rats. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Air pollution is regarded as an important risk factor for many diseases that affect a large proportion of the human population. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The highest density of microbes resides in human gastrointestinal tract, known as "Gut microbiome". 3 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source
Our findings suggest that antiplatelet or anticoagulant medication, hypertension, or minor head trauma are most likely to precipitate cerebral hemorrhage in patients with CAA who are also epsilon2 carriers. 5 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
A significant interaction between diabetes and APOE genotype exists, where diabetes affected cognitive decline in APOE3 carriers and APOE2 carriers, but not APOE4 carriers. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid plaques, consisting of deposited beta-amyloid (Aβ), are a neuropathological hallmark of Alzheimer's Disease (AD). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The ApoE-ε4 gene is a well-established genetic risk factor for neurodegenerative diseases, such as Alzheimer's disease and multiple sclerosis, which are characterized by axonal demyelination in the central nervous system. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
After more than 10 years of accumulated efforts, genome-wide association studies (GWAS) have led to many findings, most of which have been deposited into the GWAS Catalog. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 3,290 studies in this tag that have a study page, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →